CJC-1295
FDA reports limited clinical data and serious events associated with the compound.
Keep the safety limits visible.
FDA identifies immunogenicity concerns for certain routes of compounded CJC-1295 and complexities involving impurities and active-ingredient characterization.
The agency reports serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction. It says available clinical data are limited. Association in the source should not be converted into a claim that every route or product has the same outcome.
A compounding nomination is not drug approval or evidence of an anti-aging benefit. This note offers no dosing, regimen, seller links or treatment endorsement.
Interpretation is limited to the source linked above. Independent medical review pending.